Friday, 20 Oct 2017

You are here

RheumNow Week in Review – 12 August 2016

Highlights from this week on RheumNow.com include:

  1. ViDEO: Pearls on Methotrexate side effect management from Dr. Jack Cush at 2016 RNS meeting. Thanks to Healio! https://t.co/6zUJHRbbxF
  2. Great review of Raynauds Phenomenon in NEJM by Dr. Fred Wigley https://t.co/pzxpQlNQFH
  3. 10 Essential Facts about Seronegative #RA. It's the symptoms, not the labs that count most. 20% of RA is seronegative https://t.co/gEPqK3OXHT
  4. Walgreens establishes disposal “kiosk” for patients needing to discard old/dangerous/narcotic meds. . https://t.co/aDp5963Kq8 https://t.co/oigv282jZH
  5. In Japan, persistence on biologics highest in biologic-naïve (>95%) and older Pts & lowest w/ more comorbidities. https://t.co/4VTDOCpZeJ
  6. Should low-dose prednisone be used in Osteoarthritis? Conflicting data in RCTs https://t.co/7RhGFvGkD4 https://t.co/HKx7pi0K1s
  7. There are 3 kinds "hip pain" - 1 Buttock pain (70% from LS spine); 2. Side/trochanteric pain (20% from FM, Bursitis); 3. Anterior/groin (true hip Jt) (<10%)
  8. A single center 9 yr follow up study of 97 myositis saw 25% died, most from Infx(29%). Death increased w/ lung Dz (HR 1.8), infection (HR 4.2) https://t.co/c6Vp9BuN94
  9. There is No Added Lymphoma Risk with TNF Inhibitor Use
  10. Etanercept May Lower Alzheimers Risk in Rheumatoid Arthritis
  11. Cryptochromes Regulate Circadian Inflammation in RA
  12. 2016 EULAR Update to Gout Guidelines
  13. My Nurse Practitioner
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review - 20 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses presentations from APLAR 2017 in Dubai, Catastrophic APS, safety of low-dose prednisone, frequency of psoriatic arthritis and a new drug for PsA and a hepatitis A outbreak in San Diego.

13 October 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!

The Big Need - NPs and PAs

Despite being one of the most satisfying of medical subspecialties, the number of U.S. rheumatologists is about to sharply decline.  These data were presented at the 2016 ACR meeting, where it was shown that the estimated total number of U.S. rheumatologists in in 2015 was 4,933 and is projected decrease to 3,645 by 2025. During this declining clinical supply, there will be a 138% increase in demand from 6,155 to 8,184 by 2030.

Arthritis Burden over $303 Billion Annually in U.S.

Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.